dc.contributor.author | Eltlhe, Hadeel Abdnasser Azouz | |
dc.date.accessioned | 2019-04-20T10:29:19Z | |
dc.date.available | 2019-04-20T10:29:19Z | |
dc.date.issued | 2018-04-14 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/695 | |
dc.description | Osteoarthritis (OA) is the most common chronic joint disorder, and it causes detrimental effects
on the quality of life and functional status. These are characterized by progressively occurring
cartilage destruction, osteophyte formation, and subchondral sclerosis1, 2). The
histopathological findings of OA show that homeostasis between the destruction and repair
mechanisms of the joint cartilage is disturbed by the increased expression of inflammatory
reaction . This causes degradation of the joints along with the insufficiency in the synthesis of
growth factors and anti-inflammatory cytokines leading to pain, stiffness and swelling | en_US |
dc.description.abstract | Osteoarthritis, also called degenerative joint disease, is the most common type of joint disease
and is one of the 10 most disabling conditions in developed nations. It is characterized by the
progressive erosion of articular cartilage and inflammatory cells.
The promising therapeutic potential and regenerative properties of platelet-rich plasma (PRP)
have rapidly led to its widespread clinical use in musculoskeletal injury and disease. Although
the basic scientific rationale surrounding PRP products is compelling, the clinical application
has outpaced the research. Objective. The purpose of this report is to examine the current
concepts around the clinical application of PRP in OR in the knee | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Platelet-rich plasma (PRP) for osteoarthritis (OA) of the knee | en_US |
dc.type | Other | en_US |